BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT05444478
What this study is testing
What is Lenvatinib?
Lenvatinib is an investigational medicine, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma；
- recurrent HCC without any tumor related therapy；
- Tumor number ≤3；
- Tumor size ≤5cm;
- Good performance, KPS≥90；
You likely can't join if
- disagreeing to receive follow-up observation and participate the clinical study;
- Accompanying with a history of other malignancies;
- Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;
- with extrahepatic metastasis or lymph metastasis;
- receiving system therapy such as targeted therapy or immunotherapy;
- receiving local therapy such as ablation or TACE;
See the full eligibility criteria
- Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma；
- recurrent HCC without any tumor related therapy；
- Tumor number ≤3；
- Tumor size ≤5cm;
- Good performance, KPS≥90；
- Age：18-75
- Child-Pugh A or B（score of the B level is no more than 7）
- Baseline laboratory examinations meet the Criteria： Leukocyte ≥3.0×109/L； Blood platelet ≥75×109/L； Hemoglobin ≥100g/L； ALT、AST ≤ 3 x limit of normal（ULN）； Serum creatinine ≤ 1.5 x ULN； Prothrombin time \< ULN+4 s；INR...
- disagreeing to receive follow-up observation and participate the clinical study;
- Accompanying with a history of other malignancies;
- Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;
- with extrahepatic metastasis or lymph metastasis;
- receiving system therapy such as targeted therapy or immunotherapy;
- receiving local therapy such as ablation or TACE;
- Any of the following occurred within 12 months of the study: myocardial infarction, severe / unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient...
- other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or...
The study team makes the final eligibility decision.
Where it's taking place
- Changsha, Hunan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changsha, Hunan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.